ArticleAsian Pacific journal of cancer prevention : APJCP2023
Study on Breast Cancer in Kazakhstan Using the Functional Time Series.
Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Breast Cancer in Kazakhstan, 2004-2023: Successful Mortality Reduction Driven by Organized Screening and Stage Shift.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Analysis of the Effectiveness and Coverage of Breast, Cervical, and Colorectal Cancer Screening Programs in Kazakhstan for the Period 2021-2023: Regional Disparities and Coverage Dynamics.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.Oncotarget · 2023Article
- Screening for Breast, Cervical and Prostate Cancers in Kazakhstan: Key Factors and Psychological Aspects.Asian Pacific journal of cancer prevention : APJCP · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn Kazakhstan and Central Asia, breast cancer (BC) is the most common malignancy among women. However, no large-scale study on breast cancer using the functional time series approach has been carried out in Kazakhstan.
methodsA functional assessment of the age-period-cohort model (APC) and the survival rate (period 2017-2021) was used in the retrospective study. Clinical and demographic information on patients was analysed, including age, gender, region of residence, kind and stage of tumour, occupation, socioeconomic standing, nationality, and specifics of treatment and its outcomes. Additionally, the relationship between nationality, stage, and residency region and the survival rate of breast cancer patients was investigated too.
resultsThe data of n=22,736 breast cancer patients were analysed. The highest number of breast cancer cases reported was 4,945 (21.7%), in 2019. In 2021, n =4,939 (21.7%) cases were detected, while in 2020, n=4,222 (18.6%) cases were observed. The patients with breast cancer in stages I and Ia were recognized in 6,585 (29% of cases), while those in stages Ib and Ic were confirmed in 8687 (38.2% of cases). In n=10,147 (44.6%) cases, a malignant tumour of the upper outer quadrant of the breast (C50.4) was predominant. Kazakhs made up the majority (n=10,939, 48.1%) of patients with a primary validated diagnosis of breast cancer, followed by Russians (n=7527, 33.1%). Germans had the lowest survival rate overall (11.4 ± 1.7 months) (p ≤ 0.05) (95% CI: 8.0-14.7 months). Uzbeks showed relatively high survival rates of 18.3 ± 1.6 months (95% CI: 15.1-21.5 months) (p ≤ 0.05). The Aktobe region had the lowest breast cancer survival rates, measuring 12.1±0.9 months (95% CI: 10.3-13.9 months) (p ≤ 0.05). The highest survival rates, 18.0±1.3 months (95% CI: 15.5-20.5 months) and 17.9±1.4 months (95% CI: 15.3-20.7 months), were seen in Shymkent and Zhambyl regions (p ≤ 0.05), respectively. The prevalence of breast cancer increases after 37.5 years, according to the results of the APC analysis, with an indicator of 0.572 (95% CI: -0.41 - 1.56), maintaining a steady upward trend in the age range from 42.5 years to 62.5 years.
conclusionsDespite a slight drop in the disease's frequency, the incidence of breast cancer in women 37.5 years and older has been stable over the past five years. Additionally, it was shown that the country's northern regions had a higher incidence of breast cancer cases than the southern and western regions. Our results show the significance of demographic characteristics such as age and location for the development of preventive measures and effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.